Factors associated with recovery from acute optic neuritis in patients with multiple sclerosis

Neurology

Volumn 82, Issue 24, 2014, Pages 2173-2179

  Malik, Muhammad Taimur ^a   Healy, Brian C ^a   Benson, Leslie A ^a,b,c   Kivisakk, Pia ^a   Musallam, Alexander ^a   Weiner, Howard L ^a   Chitnis, Tanuja ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D;

ADULT; AGE; ARTICLE; BLOOD SAMPLING; CLINICAL FEATURE; DEMOGRAPHY; DISABILITY; DISEASE SEVERITY; DRUG TARGETING; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; PRIORITY JOURNAL; SYMPTOM; VISUAL ACUITY; VITAMIN BLOOD LEVEL;

ADOLESCENT; ADULT; AGE FACTORS; CHILD; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MULTIPLE SCLEROSIS; OPTIC NEURITIS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; VISUAL ACUITY; VITAMIN D; YOUNG ADULT;

EID: 84904015568     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000524     Document Type: Article

References (31)

1. Beck RW, Gal RL. Treatment of acute optic neuritis: a summary of findings from the optic neuritis treatment trial. Arch Ophthalmol 2008;126: 994-995.
2. Burman J, Raininko R, Fagius J. Bilateral and recurrent optic neuritis in multiple sclerosis. Acta Neurol Scand 2011;123: 207-210.
3. Mowry EM, Deen S, Malikova I, Pelletier J, Bacchetti P, Waubant E. The onset location of multiple sclerosis predicts the location of subsequent relapses. J Neurol Neurosurg Psychiatry 2009;80: 400-403.
4. Fay AJ, Mowry EM, Strober J, Waubant E. Relapse severity and recovery in early pediatric multiple sclerosis. Mult Scler 2012;18: 1008-1012.
5. Benson LA, Healy BC, Gorman MP, et al. Elevated relapse rates in pediatric compared to adult MS persist for at least 6 years. Mult Scler Relat Disord 2014;3: 186-193.
6. Renoux C, Vukusic S, Mikaeloff Y, et al. Natural history of multiple sclerosis with childhood onset. N Engl J Med 2007;356: 2603-2613.
7. Gorman MP, Healy BC, Polgar-Turcsanyi M, Chitnis T. Increased relapse rate in pediatric-onset compared with adultonset multiple sclerosis. Arch Neurol 2009;66: 54-59.
8. Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol 2010;67: 618-624.
9. Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol 2012;72: 234-240.
10. Gauthier SA, Glanz BI, Mandel M, Weiner HL. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB Study. Autoimmun Rev 2006;5: 532-536.
11. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011;69: 292-302.
12. West T, Wyatt M, High A, Bostrom A, Waubant E. Are initial demyelinating event recovery and time to second event under differential control? Neurology 2006;67: 809-813.
13. Beck RW, Cleary PA, Anderson MM Jr, et al. A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. The Optic Neuritis Study Group. N Engl J Med 1992;326: 581-588.
14. Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE Trial. Neurology 2002; 59: 1496-1506.
15. Optic Neuritis Study Group. Multiple sclerosis risk after optic neuritis: final optic neuritis treatment trial follow-up. Arch Neurol 2008;65: 727-732.
16. Meadows SP. Doyne memorial lecture (1969): retrobulbar and optic neuritis in childhood and adolescence. Trans Ophthalmol Soc UK 1970;89: 603-638.
17. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-Analysis of randomized controlled clinical trials. J Neurol 2000;247: 435-442.
18. Mowry EM, Pesic M, Grimes B, Deen S, Bacchetti P, Waubant E. Demyelinating events in early multiple sclerosis have inherent severity and recovery. Neurology 2009; 72: 602-608.
19. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296: 2832-2838.
20. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol 2010;68: 193-203.
21. Himmelstein S, Clemens TL, Rubin A, Lindsay R. Vitamin D supplementation in elderly nursing home residents increases 25(OH)D but not 1,25(OH)2D. Am J Clin Nutr 1990;52: 701-706.
22. Davie MW, Lawson DE, Emberson C, Barnes JL, Roberts GE, Barnes ND. Vitamin D from skin: contribution to vitamin D status compared with oral vitamin D in normal and anticonvulsant-Treated subjects. Clin Sci 1982;63: 461-472.
23. Bove RM, Chitnis T. Sexual disparities in the incidence and course of MS. Clin Immunol 2013;149: 201-210.
24. Bergamaschi R. Prognostic factors in multiple sclerosis. Int Rev Neurobiol 2007;79: 423-447.
25. Weinshenker BG, Rice GP, Noseworthy JH, Carriere W, Baskerville J, Ebers GC. The natural history of multiple sclerosis: a geographically based study: 3: multivariate analysis of predictive factors and models of outcome. Brain 1991;114: 1045-1056.
26. Glad SB, Nyland HI, Aarseth JH, Riise T, Myhr KM. Long-Term follow-up of benign multiple sclerosis in Hordaland County, Western Norway. Mult Scler 2009; 15: 942-950.
27. Kantarci O, Siva A, Eraksoy M, et al. Survival and predictors of disability in Turkish MS patients. Turkish Multiple Sclerosis Study Group (TUMSSG). Neurology 1998; 51: 765-772.
28. Gold SM, Voskuhl RR. Estrogen and testosterone therapies in multiple sclerosis. Prog Brain Res 2009;175: 239-251.
29. Palaszynski KM, Loo KK, Ashouri JF, Liu HB, Voskuhl RR. Androgens are protective in experimental autoimmune encephalomyelitis: implications for multiple sclerosis. J Neuroimmunol 2004;146: 144-152.
30. Maccio DR, Calfa G, Roth GA. Oral testosterone in male rats and the development of experimental autoimmune encephalomyelitis. Neuroimmunomodulation 2005;12: 246-254.
31. Trojano M, Liguori M, Bosco Zimatore G, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002;51: 475-480.